operating-room
(6)
Robert Masson
Robert Masson is a neurosurgeon turned founder who runs eXeX (Expanded Existence), an AI and mixed-reality platform that captures surgical mastery and pipes holographic guidance into the sterile field. With more than three decades of spine surgery and 13,000-plus procedures behind him, he made global headlines for bringing the Apple Vision Pro into the operating room as a touch-free logistics tool. He is also the founder of the Masson Spine Institute and, at 52, raced to a podium at the Rolex 24 at Daytona alongside his eldest son.
Sam Weinstein
Sam Weinstein is a pediatric cardiac surgeon turned healthcare executive who runs SpecialtyCare, the Brentwood, Tennessee company that supplies the specialized clinical teams - perfusionists, neuromonitoring technologists, surgical assistants and sterile-processing staff - working inside more than 1,200 hospital operating rooms across 45 states. After 16 years operating on children's hearts in New York and leading more than 30 surgical mission trips to Latin America, he joined SpecialtyCare as Chief Medical Officer in 2015, became President of Operations in 2016, and has been CEO since 2017. His pitch is simple: take the largest operative procedural database in the business and use it to make surgery safer and cheaper, one case at a time.
David Schummers
David Schummers is the co-founder and CEO of Apella Technology, a San Francisco-based ambient AI company transforming how hospitals run their operating rooms. Using computer vision and machine learning, Apella captures real-time surgical intelligence - automatically documenting up to 14 case events per procedure and feeding structured data back into EHR systems - reducing OR turnover times by 16% and increasing case volume by 10%. Before founding Apella in 2019, Schummers spent two decades in health technology, including a pivotal stint at Auris Health as its first commercial executive, where he helped engineer the company's $5.7 billion acquisition by Johnson & Johnson in 2019 - at the time the largest medical technology startup transaction in history. Apella raised an $80 million Series B in January 2026 led by HighlandX, bringing total funding to over $104 million.
Keith Carter
Keith Carter is a healthcare technology operator with deep roots in medical imaging and surgical data infrastructure. Currently VP of Implementations & Integrations at Caresyntax - the AI-powered surgical intelligence platform used in 3,500+ operating rooms worldwide - he also serves as CEO of Cloud9PACS.com, a digital PACS system he built from the ground up. Carter's career traces the arc of healthcare IT: from PACS architect at Medlink to running his own imaging solutions company, to joining one of the most-funded surgical AI ventures in the industry. He is based in Hattiesburg, Mississippi.
Matt Krueger
Matt Krueger is the Chief Executive Officer of Caresyntax, an AI-powered surgical intelligence platform used in 4,200+ operating rooms worldwide and supporting over 3 million surgical procedures annually. A decade-long veteran of the company, Krueger rose through roles including SVP & GM for the Americas & ANZ, Chief Commercial Officer, Chief Customer Officer, and President before being elevated to CEO in July 2025. With 18+ years in medical devices and healthcare technology - including stints at Hill-Rom and TRUMPF - he has been a primary architect of Caresyntax's expansion and its consistent 50%+ organic revenue growth trajectory.
Mudit Garg
Mudit Garg is the co-founder and CEO of Qventus, a Mountain View-based AI healthcare company that automates hospital operations — from surgical scheduling to patient discharge. Trained as an electrical engineer at IIT and holding an MBA from Stanford, Garg spent time at McKinsey's healthcare practice before founding Qventus in 2012. Under his leadership, the company raised a $105M Series D led by KKR in January 2025, reached a valuation of over $400 million, and has helped health systems across the US free up tens of thousands of excess hospital days and generate tens of millions in surgical revenue.